Where can I find news about GSK?

The latest headlines, third-party analysis, and SEC filings for GSK plc (GSK) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are GSK's SEC filings?

GSK plc (GSK)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are GSK's earnings call transcripts?

Full earnings call transcripts for GSK plc (GSK) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

GSK

GSK plc

NYSE·Drug Manufacturers, General · Healthcare

$49.20$0.69−1.38%

Market cap$98.57B·Sep 8 2:07 PM UTC

News & Analysis

GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last weekend.
proactiveinvestors.co.ukSep 4, 2026 · 6:25 AM
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.
marketbeat.comSep 3, 2026 · 1:03 PM
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market continues to overlook the biotech's expanding oncology pipeline.
proactiveinvestors.co.ukSep 3, 2026 · 6:33 AM
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830.
proactiveinvestors.co.ukSep 3, 2026 · 3:51 AM
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay ‌a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.
reuters.comSep 3, 2026 · 1:48 AM
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
zacks.comSep 2, 2026 · 12:16 PM
Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III
Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the stock is climbing anyway.
247wallst.comSep 1, 2026 · 2:00 PM
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
zacks.comSep 1, 2026 · 10:46 AM

SEC Filings

424B2
Sep 8, 2026View on SEC
6-K
Sep 8, 2026View on SEC
6-K
Sep 1, 2026View on SEC
6-K
Sep 1, 2026View on SEC
6-K
Aug 26, 2026View on SEC
6-K
Aug 24, 2026View on SEC

Frequently Asked Questions About GSK

Where can I find news about GSK?: The latest headlines, third-party analysis, and SEC filings for GSK plc (GSK) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are GSK's SEC filings?: GSK plc (GSK)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are GSK's earnings call transcripts?: Full earnings call transcripts for GSK plc (GSK) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

GSK plc

Frequently Asked Questions About GSK

GSK plc

GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

GSK to Advance mRNA Influenza Vaccine Into Phase III Development

Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III

GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?

Frequently Asked Questions About GSK

GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

GSK to Advance mRNA Influenza Vaccine Into Phase III Development

Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III

GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?